Skip to content

Astemizole

RESPIRATORY SYSTEM

Also known as: astemisan, hismanal, histazol, R 43 512

FDA approvedATC R06AX11

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Astemizole is a drug catalogued in DrugCentral. It was first approved by the FDA in 1988. DrugCentral lists 61 molecular targets, including KCNH2, FNTA|FNTB and HRH1. Recorded indications include Allergic conjunctivitis, Allergic rhinitis, Chronic idiopathic urticaria and Sneezing.

  • Molecular targets: KCNH2, FNTA|FNTB, HRH1 and HTR2A (61 listed in DrugCentral).
  • Indications: Allergic conjunctivitis, Allergic rhinitis, Chronic idiopathic urticaria and Sneezing.
  • ATC code: R06AX11 (Other antihistamines for systemic use).
  • Molecular formula: C28H31FN4O; molecular weight 458.58 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

  • Allergic conjunctivitis
  • Allergic rhinitis
  • Chronic idiopathic urticaria
  • Sneezing

Off-label uses (1)

  • Urticaria

Mechanism & targets

Molecular targets (61)

TargetGeneActionActivity
Potassium voltage-gated channel subfamily H member 2KCNH2unknownIC50 9.05
Protein farnesyltransferaseFNTA|FNTBunknownIC50 8.70
Histamine H1 receptorHRH1antagonistA2 8.58
5-hydroxytryptamine receptor 2AHTR2AunknownKi 8.25
5-hydroxytryptamine receptor 2BHTR2BunknownKi 8.13
Alpha-1D adrenergic receptorADRA1DunknownKi 8.00
Alpha-1A adrenergic receptorAdra1aunknownIC50 7.62
5-hydroxytryptamine receptor 2CHTR2CunknownKi 7.03
Alpha-1B adrenergic receptorAdra1bunknownKi 7.02
Transmembrane protein 97TMEM97unknownKi 7.02
5-hydroxytryptamine receptor 3AHTR3AunknownKi 7.02
D(3) dopamine receptorDRD3unknownKi 6.83
Muscarinic acetylcholine receptor M3CHRM3unknownKi 6.75
Membrane-associated progesterone receptor component 1Pgrmc1unknownKi 6.73
Potassium voltage-gated channel subfamily H member 1KCNH1blockerIC50 6.70
Muscarinic acetylcholine receptor M1CHRM1unknownKi 6.59
Muscarinic acetylcholine receptor M4CHRM4unknownKi 6.59
Alpha-2C adrenergic receptorADRA2CunknownKi 6.54
5-hydroxytryptamine receptor 1AHTR1AunknownKi 6.36
Muscarinic acetylcholine receptor M2CHRM2unknownKi 6.30

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1988-12-31FDA——

ATC classification

ATC codeTherapeutic hierarchy
R06AX11RESPIRATORY SYSTEM › ANTIHISTAMINES FOR SYSTEMIC USE › ANTIHISTAMINES FOR SYSTEMIC USE › Other antihistamines for systemic use

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Astemizole is on its molecule page.

Molecular formulaC28H31FN4O
Molecular weight458.58 g/mol
CAS number68844-77-9
InChIKeyGXDALQBWZGODGZ-UHFFFAOYSA-N
PubChem CID2247
COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Astemizole used for?

DrugCentral lists the following indications for Astemizole: Allergic conjunctivitis, Allergic rhinitis, Chronic idiopathic urticaria and Sneezing.

How does Astemizole work?

Its molecular targets in DrugCentral include KCNH2, FNTA|FNTB, HRH1 (antagonist) and HTR2A.

When was Astemizole first approved?

Astemizole was first approved by the FDA in 1988.

What is the chemical formula of Astemizole?

Astemizole has the molecular formula C28H31FN4O and a molecular weight of 458.58 g/mol.

Browse: all drugs starting with A · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval1988-12-31
AgencyFDA
Targets61
Indications4
FormulaC28H31FN4O
DrugCentral ID249
Interactive profile